Before marketing a new drug that has been approved for use based on clinical effectiveness and safety, the manufacturer wishes to study the potential new uses for the drug. This is an example of which phase of study?

A. C-V drugs are considered to have the lowest potential for abuse and are typically used for medications like cough preparations with less than 200 milligrams of codeine per 100 milliliters or per 100 grams. Methadone is not classified under C-V.

B. Methadone is classified as a C-II (Schedule II) controlled substance because it has a high potential for abuse, but it also has accepted medical uses, such as for opioid withdrawal management.

C. C-I drugs are considered to have no accepted medical use and a high potential for abuse (e.g., heroin, LSD). Methadone is not classified as a C-I drug.

D. C-III drugs have a moderate potential for abuse and are generally used for medications like anabolic steroids or some barbiturates, but methadone is not classified under C-III.

A. Assessment is the first phase of the nursing process, during which the nurse gathers relevant patient data, such as allergies and lab values, to ensure safe medication administration. This step helps identify potential risks and contraindications.

B. Evaluation occurs after the medication has been administered and involves assessing the patient's response to the drug. In this case, the nurse is reviewing information before administration, making evaluation an incorrect choice.

C. Implementation refers to carrying out the nursing interventions, such as actually administering the medication. Since the nurse is still reviewing data, this step has not yet been reached.

D. Planning involves setting goals and determining appropriate interventions, but it does not include the direct collection of patient data. Reviewing lab values and allergies falls under the assessment phase.